Terms: = Ovarian cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Treatment
45 results:
1. Iron overload increases the sensitivity of endometriosis stromal cells to ferroptosis via a PRC2-independent function of ezh2.
Luo Y; Li L; Hu Q; Zhang Z; Liu F; Peng Y; Zou Y; Chen L
Int J Biochem Cell Biol; 2024 Apr; 169():106553. PubMed ID: 38417568
[TBL] [Abstract] [Full Text] [Related]
2. Dual target PARP1/ezh2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.
Li X; Wang C; Li S; Yin F; Luo H; Zhang Y; Luo Z; Chen Y; Wan S; Kong L; Wang X
Eur J Med Chem; 2024 Feb; 265():116054. PubMed ID: 38134746
[TBL] [Abstract] [Full Text] [Related]
3. Epigenetic reactivation of PEG3 by ezh2 inhibitors suppresses renal clear cell carcinoma progress.
Qiu T; Ding Y; Qin J; Ren D; Xie M; Qian Q; Wang Y; Ma L; Jing A; Yang J; Ma S; Wang X; Wang W; Ji J; Li G
Cell Signal; 2023 Jul; 107():110662. PubMed ID: 37001595
[TBL] [Abstract] [Full Text] [Related]
4. Differential effects of the LncRNA RNF157-AS1 on epithelial ovarian cancer cells through suppression of DIRAS3- and ULK1-mediated autophagy.
Xu P; Xu S; Pan H; Dai C; Xu Y; Wang L; Cong Y; Zhang H; Cao J; Ge L; Jia X
Cell Death Dis; 2023 Feb; 14(2):140. PubMed ID: 36805591
[TBL] [Abstract] [Full Text] [Related]
5. Discovery of a Novel Covalent ezh2 Inhibitor Based on Tazemetostat Scaffold for the treatment of ovarian cancer.
Zhang Q; Chen X; Cao J; Yang W; Wan G; Feng Q; Zhou S; Yang H; Wang N; Liu Z; Xiao H; Zhu Y; Yu L
J Med Chem; 2023 Feb; 66(3):1725-1741. PubMed ID: 36692394
[TBL] [Abstract] [Full Text] [Related]
6. The epigenetic factor CHD4 contributes to metastasis by regulating the ezh2/β-catenin axis and acts as a therapeutic target in ovarian cancer.
Wang J; Zhong F; Li J; Yue H; Li W; Lu X
J Transl Med; 2023 Jan; 21(1):38. PubMed ID: 36681835
[TBL] [Abstract] [Full Text] [Related]
7. Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
Huang TT; Burkett SS; Tandon M; Yamamoto TM; Gupta N; Bitler BG; Lee JM; Nair JR
Oncogene; 2022 Nov; 41(46):5020-5031. PubMed ID: 36224341
[TBL] [Abstract] [Full Text] [Related]
8. FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through ezh2-mediated H3K27me3.
Xiong X; Lai X; Zhang J; Meng Q; Wang P; Qin S; Liu W; Wang Y; Yao Z; Wang D; Li X; Liu Z; Miao H
Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 36000567
[TBL] [Abstract] [Full Text] [Related]
9. Dual G9A/ezh2 Inhibition Stimulates Antitumor Immune Response in ovarian High-Grade Serous Carcinoma.
Spiliopoulou P; Spear S; Mirza H; Garner I; McGarry L; Grundland-Freile F; Cheng Z; Ennis DP; Iyer N; McNamara S; Natoli M; Mason S; Blyth K; Adams PD; Roxburgh P; Fuchter MJ; Brown B; McNeish IA
Mol Cancer Ther; 2022 Apr; 21(4):522-534. PubMed ID: 35131874
[TBL] [Abstract] [Full Text] [Related]
10. ezh2-mediated lncRNA ABHD11-AS1 promoter regulates the progression of ovarian cancer by targeting miR-133a-3p.
Zhang W; Huang X; Shi J
Anticancer Drugs; 2021 Mar; 32(3):269-277. PubMed ID: 33491971
[TBL] [Abstract] [Full Text] [Related]
11. Downregulation of hsa_circ_0026123 suppresses ovarian cancer cell metastasis and proliferation through the miR‑124‑3p/ezh2 signaling pathway.
Yang X; Wang J; Li H; Sun Y; Tong X
Int J Mol Med; 2021 Feb; 47(2):668-676. PubMed ID: 33416105
[TBL] [Abstract] [Full Text] [Related]
12. Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated ezh2 and SIRT1.
Zhang Y; Ai H; Fan X; Chen S; Wang Y; Liu L
Biol Res; 2020 Apr; 53(1):18. PubMed ID: 32349783
[TBL] [Abstract] [Full Text] [Related]
13. Identification of key genes and pathways associated with topotecan treatment using multiple bioinformatics tools.
Kang YM; Lan A; Huang YH; Hsu KM; Chao Y; Lan KL
J Chin Med Assoc; 2020 May; 83(5):446-453. PubMed ID: 32243271
[TBL] [Abstract] [Full Text] [Related]
14. Precision medicine for ovarian clear cell carcinoma based on gene alterations.
Kuroda T; Kohno T
Int J Clin Oncol; 2020 Mar; 25(3):419-424. PubMed ID: 32020380
[TBL] [Abstract] [Full Text] [Related]
15. UNC5B-AS1 promoted ovarian cancer progression by regulating the H3K27me on NDRG2 via ezh2.
Wang H; Su H; Tan Y
Cell Biol Int; 2020 Apr; 44(4):1028-1036. PubMed ID: 31903696
[TBL] [Abstract] [Full Text] [Related]
16. Mechanisms of PARP inhibitor resistance in ovarian cancer.
Kubalanza K; Konecny GE
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):36-41. PubMed ID: 31815769
[TBL] [Abstract] [Full Text] [Related]
17. ezh2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous ovarian cancers Expressing ATM.
Naskou J; Beiter Y; van Rensburg R; Honisch E; Rudelius M; Schlensog M; Gottstein J; Walter L; Braicu EI; Sehouli J; Darb-Esfahani S; Staebler A; Hartkopf AD; Brucker S; Wallwiener D; Beyer I; Niederacher D; Fehm T; Templin MF; Neubauer H
Mol Cancer Res; 2020 Feb; 18(2):278-286. PubMed ID: 31704732
[TBL] [Abstract] [Full Text] [Related]
18. Long non-coding RNA SNHG6 promotes cell proliferation and migration through sponging miR-4465 in ovarian clear cell carcinoma.
Wu Y; Deng Y; Guo Q; Zhu J; Cao L; Guo X; Xu F; Weng W; Ju X; Wu X
J Cell Mol Med; 2019 Aug; 23(8):5025-5036. PubMed ID: 31119871
[TBL] [Abstract] [Full Text] [Related]
19. The histone methyltransferase WHSC1 is regulated by ezh2 and is important for ovarian clear cell carcinoma cell proliferation.
Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Machino H; Honjoh H; Kawata Y; Kashiyama T; Asada K; Tanikawa M; Mori-Uchino M; Tsuruga T; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
BMC Cancer; 2019 May; 19(1):455. PubMed ID: 31092221
[TBL] [Abstract] [Full Text] [Related]
20. ezh2 Is Overexpressed in
Puppe J; Opdam M; Schouten PC; Jóźwiak K; Lips E; Severson T; van de Ven M; Brambillasca C; Bouwman P; van Tellingen O; Bernards R; Wesseling J; Eichler C; Thangarajah F; Malter W; Pandey GK; Ozretić L; Caldas C; van Lohuizen M; Hauptmann M; Rhiem K; Hahnen E; Reinhardt HC; Büttner R; Mallmann P; Schömig-Markiefka B; Schmutzler R; Linn S; Jonkers J
Clin Cancer Res; 2019 Jul; 25(14):4351-4362. PubMed ID: 31036541
[TBL] [Abstract] [Full Text] [Related]
[Next]
